Organogenesis Holdings Inc (ORGO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Organogenesis Holdings Inc stock (ORGO) is currently trading at $2.44. Organogenesis Holdings Inc PE ratio is 16.47. Organogenesis Holdings Inc PS ratio (Price-to-Sales) is 0.56. Analyst consensus price target for ORGO is $8.00. WallStSmart rates ORGO as Moderate Buy.
- ORGO PE ratio analysis and historical PE chart
- ORGO PS ratio (Price-to-Sales) history and trend
- ORGO intrinsic value — DCF, Graham Number, EPV models
- ORGO stock price prediction 2025 2026 2027 2028 2029 2030
- ORGO fair value vs current price
- ORGO insider transactions and insider buying
- Is ORGO undervalued or overvalued?
- Organogenesis Holdings Inc financial analysis — revenue, earnings, cash flow
- ORGO Piotroski F-Score and Altman Z-Score
- ORGO analyst price target and Smart Rating
Organogenesis Holdings Inc
📊 No data available
Try selecting a different time range
ORGO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Organogenesis Holdings Inc (ORGO)
ORGO trades at a significant discount to its Graham intrinsic value of $7.02, offering a 47% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Organogenesis Holdings Inc (ORGO) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, price/sales, price/book. Concerns around return on equity. Overall metrics suggest strong investment potential with favorable risk/reward.
Organogenesis Holdings Inc (ORGO) Key Strengths (6)
Paying less than $1 for every $1 of annual revenue
Revenue surging 78.10% year-over-year
Earnings per share surging 555.00% year-over-year
Strong operational efficiency: $29 kept per $100 revenue
Trading at 1.02x book value, attractively priced
54.55% held by institutions, strong professional interest
Supporting Valuation Data
Organogenesis Holdings Inc (ORGO) Areas to Watch (3)
Low profitability relative to shareholder equity
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Organogenesis Holdings Inc (ORGO) Detailed Analysis Report
Overall Assessment
This company scores 67/100 in our Smart Analysis, earning a B- grade. Out of 9 metrics analyzed, 6 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 4.0/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth, EPS Growth. Valuation metrics including Price/Sales (0.56), Price/Book (1.02) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 28.90%. Growth metrics are encouraging with Revenue Growth at 78.10%, EPS Growth at 555.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Market Cap. Profitability pressure is visible in Return on Equity at 9.04%, Profit Margin at 6.56%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 9.04% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 78.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Sales, Revenue Growth) and negatives (Return on Equity, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ORGO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ORGO's Price-to-Sales ratio of 0.56x sits near its historical average of 0.62x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 22% below its historical high of 0.72x set in Mar 2026, and 2% above its historical low of 0.55x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.7x as trailing revenue scaled faster than the stock price.
Compare ORGO with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Organogenesis Holdings Inc (ORGO) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Organogenesis Holdings Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 564M with 78% growth year-over-year. Profit margins are thin at 6.6%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 78% YoY, reaching 564M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 35M in free cash flow and 39M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Organogenesis Holdings Inc push profit margins above 15% as the business scales?
Growth sustainability: can Organogenesis Holdings Inc maintain 78%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Organogenesis Holdings Inc.
Bottom Line
Organogenesis Holdings Inc is a high-conviction growth story with revenue accelerating at 78% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 6.6% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Organogenesis Holdings Inc(ORGO)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.